Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:GMAB NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$209.79-1.6%$232.61$160.86▼$250.74$13.30B0.39528,100 shs387,645 shsBBIOBridgeBio Pharma$67.40-0.4%$70.51$38.57▼$84.94$13.26B0.972.75 million shs2.13 million shsGMABGenmab A/S$24.49-2.4%$26.84$20.23▼$35.43$15.65B0.851.93 million shs876,186 shsTNGXTango Therapeutics$28.68-9.1%$23.09$4.32▼$32.79$4.57B1.194.05 million shs9.85 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+3.61%-1.56%-10.66%-6.27%+23.15%BBIOBridgeBio Pharma+0.46%+5.95%+0.43%-5.20%+73.41%GMABGenmab A/S+1.21%+5.24%-4.88%-8.33%+12.81%TNGXTango Therapeutics+2.04%+46.79%+37.10%+85.76%+658.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$209.79-1.6%$232.61$160.86▼$250.74$13.30B0.39528,100 shs387,645 shsBBIOBridgeBio Pharma$67.40-0.4%$70.51$38.57▼$84.94$13.26B0.972.75 million shs2.13 million shsGMABGenmab A/S$24.49-2.4%$26.84$20.23▼$35.43$15.65B0.851.93 million shs876,186 shsTNGXTango Therapeutics$28.68-9.1%$23.09$4.32▼$32.79$4.57B1.194.05 million shs9.85 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+3.61%-1.56%-10.66%-6.27%+23.15%BBIOBridgeBio Pharma+0.46%+5.95%+0.43%-5.20%+73.41%GMABGenmab A/S+1.21%+5.24%-4.88%-8.33%+12.81%TNGXTango Therapeutics+2.04%+46.79%+37.10%+85.76%+658.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3940.80% UpsideBBIOBridgeBio Pharma 2.85Moderate Buy$89.5932.92% UpsideGMABGenmab A/S 2.75Moderate Buy$37.9354.87% UpsideTNGXTango Therapeutics 2.71Moderate Buy$38.4233.95% UpsideCurrent Analyst Ratings BreakdownLatest TNGX, GMAB, ASND, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026TNGXTango Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $66.006/9/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $42.006/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/8/2026TNGXTango Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.006/8/2026TNGXTango Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetPeer Perform ➝ Outperform$35.006/8/2026TNGXTango Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026TNGXTango Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$55.00 ➝ $69.006/8/2026TNGXTango Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/28/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.00(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$865.78M15.11N/AN/A($2.97) per share-70.64BBIOBridgeBio Pharma$502.08M26.29N/AN/A($10.77) per share-6.26GMABGenmab A/S$3.72B4.10$1.57 per share15.59$9.10 per share2.69TNGXTango Therapeutics$62.38M66.50N/AN/A$2.57 per share11.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6724.2019.53N/A57.87%N/A-8.37%8/6/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A293.04N/A-124.42%N/A-65.81%8/4/2026 (Estimated)GMABGenmab A/S$963M$1.3218.5514.581.4921.05%15.34%8.94%8/6/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/A-151.15%-41.54%-33.44%8/4/2026 (Estimated)Latest TNGX, GMAB, ASND, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BBIOBridgeBio PharmaN/A1.521.48GMABGenmab A/S0.872.182.17TNGXTango TherapeuticsN/A27.3827.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%GMABGenmab A/S7.07%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%GMABGenmab A/S1.54%TNGXTango Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableGMABGenmab A/S3,029623.53 million613.93 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableTNGX, GMAB, ASND, and BBIO HeadlinesRecent News About These CompaniesIs Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year3 hours ago | finance.yahoo.comTango Therapeutics Announces Major Underwritten Equity Offering4 hours ago | tipranks.comTango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsJune 9 at 11:11 PM | quiverquant.comQTango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingJune 9 at 10:49 PM | globenewswire.comTango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk AppetiteJune 9 at 3:10 PM | seekingalpha.comTango Therapeutics (TNGX) stock soars on pancreatic cancer trial resultsJune 9 at 2:51 PM | msn.comTNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsJune 9 at 1:46 PM | zacks.comTango shares surge on early pancreatic cancer combination dataJune 9 at 9:51 AM | thepharmaletter.comTTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer TranscriptJune 8 at 5:00 PM | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8 at 4:04 PM | invezz.comITango Therapeutics Announces Proposed $500 Million Public OfferingJune 8 at 4:01 PM | globenewswire.comTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer - SlideshowJune 8 at 4:00 PM | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8 at 3:55 PM | invezz.comIStock Movers: Intel, Tango Therapeutics, StrategyJune 8 at 3:04 PM | bloomberg.comTNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’June 8 at 3:04 PM | msn.comTango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer TreatmentJune 8 at 1:00 PM | barrons.comTango skyrockets 47% on eye-popping pancreatic cancer resultsJune 8 at 10:03 AM | msn.comTango Therapeutics' pancreatic cancer drug combo shows promise in studyJune 8 at 8:15 AM | reuters.comTango Therapeutics Reports Encouraging Initial Phase 1/2 Data on Vopimetostat and Daraxonrasib Combination for Treatment of MTAP-Deleted Pancreatic CancerJune 8 at 7:11 AM | quiverquant.comQTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerJune 8 at 6:59 AM | globenewswire.comVanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGXMay 15, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNGX, GMAB, ASND, and BBIO Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$209.79 -3.44 (-1.61%) Closing price 04:00 PM EasternExtended Trading$210.04 +0.25 (+0.12%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$67.40 -0.28 (-0.41%) Closing price 04:00 PM EasternExtended Trading$66.09 -1.31 (-1.94%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Genmab A/S NASDAQ:GMAB$24.49 -0.61 (-2.43%) Closing price 04:00 PM EasternExtended Trading$24.50 +0.01 (+0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Tango Therapeutics NASDAQ:TNGX$28.68 -2.88 (-9.13%) Closing price 04:00 PM EasternExtended Trading$28.70 +0.02 (+0.07%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Everpure: AI Storage Uncertainty Overshadows Breakneck Growth This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason FuelCell Energy Just Got a Wake-Up Call From Wall Street Intel Is the Market's Most Mispriced AI Hedge Palantir's AIPCon Shows Why Customers Are Fueling the Bull Case Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
